While the frontline treatment landscape expands for lower-risk myelodysplastic syndrome (LR-MDS), providers are faced with new opportunities and challenges to individualizing care. Join leading LR-MDS experts in this research-informed webcast as they divulge real-world challenges to integrating novel LR-MDS therapies and mitigating treatment-related adverse events identified through a recent hematology/oncology provider survey. The expert faculty will also take the audience through complex clinical cases, sharing real-world perspectives with various "what if" scenarios to explore key nuances of decision-making regarding dose titration and adverse event management. Tune in to equip yourself with evidence-based strategies to individualize frontline treatment plans for LR-MDS patients.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/moving-needle-adopting-new-evidence-into-lower-risk-myelodysplastic-syndrome
- Start Date: 2024-07-10 05:00:00
- End Date: 2024-07-10 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 79750.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all